Loading…
Tango Therapeutics, Inc. is projected to rise to $32.99 by 2027, a +20% move from its current price of $27.57. TNGX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $26.50 | $27.59 | $28.73 | +0.08% |
| Aug 2 | $26.07 | $27.61 | $29.24 | +0.16% |
| Aug 3 | $25.76 | $27.64 | $29.65 | +0.24% |
| Aug 4 | $25.50 | $27.66 | $29.99 | +0.31% |
| Aug 5 | $25.28 | $27.68 | $30.30 | +0.39% |
| Aug 6 | $25.08 | $27.70 | $30.59 | +0.47% |
| Aug 7 | $24.90 | $27.72 | $30.86 | +0.55% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $24.90 | $27.72 | $30.86 | +0.55% |
| Week 2 | $23.95 | $27.87 | $32.44 | +1.11% |
| Week 3 | $23.28 | $28.03 | $33.75 | +1.66% |
| Week 4 | $22.74 | $28.18 | $34.93 | +2.22% |
| Week 5 | $22.30 | $28.34 | $36.02 | +2.79% |
| Week 6 | $21.91 | $28.49 | $37.06 | +3.35% |
| Week 7 | $21.57 | $28.65 | $38.05 | +3.92% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Tango Therapeutics, Inc. is a healthcare company focused on precision oncology. It concentrates on the discovery and development of drugs in defined patient populations with unmet medical need.
The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Tango Therapeutics, Inc. trades under the symbol TNGX and is categorized in Healthcare. It currently prices at $27.64 per share and has a market cap of $4.5B, with a rank of 1429. These data points place the stock within a mid-cap healthcare segment in the market landscape.
The near-term technical backdrop shows a bullish tilt, even as real-time levels remain close to the current price.
A major floor 31.2% below — a decisive break under it would weaken the trend.
The nearest floor, 6.2% below — buyers have tended to step in here.
The nearest ceiling, 18.1% above — a clean break opens room to run.
A major ceiling 28.3% above — clearing it would confirm fresh momentum.
Key TNGX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TNGX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $26.68 | Buy | $26.98 | Buy |
| MA 10 | $27.41 | Buy | $27.42 | Buy |
| MA 20 | $28.59 | Sell | $28.00 | Sell |
| MA 50 | $27.25 | Buy | $27.14 | Buy |
| MA 100 | $24.50 | Buy | $24.16 | Buy |
| MA 200 | $17.37 | Buy | $19.33 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.32 | Neutral |
| Stoch RSI (14) | 53.42 | Neutral |
| CCI (20) | -50.64 | Neutral |
| Williams %R (14) | -60.91 | Info |
| MACD (12,26,9) | -0.38 | Sell |
| ROC (12) | -7.02 | Sell |
| Bollinger %B (20,2) | 0.33 | Neutral |
| Stochastic %K (14) | 39.09 | Neutral |
| TRIX (15) | -0.03 | Sell |
| Awesome (5,34) | -2.67 | Sell |
| Ultimate (7,14,28) | 38.54 | Neutral |
| Momentum (10) | -0.07 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 26.23 | Buy |
| ADX (14) | 11.02 | Neutral |
| ATR (14) | 1.04 | Info |
The 30-day technical picture is bullish. The sentiment is BULLISH and the RSI(14) is 50, with the 50-day simple moving average at $26.43 and the 200-day simple moving average at $16.38. Support is noted at $20.22 and resistance at $32.90.
The 30-day price range runs from $20.18 to $37.85, indicating a wide but upward-leaning swing, while annualized volatility stands at 90%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.91 | $27.57 | $42.98 | 0% | Neutral | |
| $25.15 | $32.99 | $46.40 | +20% | Neutral | |
| $30.63 | $42.00 | $62.23 | +52% | Bullish | |
| $39.61 | $56.37 | $86.93 | +104% | Bullish | |
| $45.42 | $66.80 | $106.50 | +142% | Bullish | |
| $50.37 | $76.38 | $125.34 | +177% | Bullish | |
| $48.83 | $76.18 | $128.26 | +176% | Bullish | |
| $50.04 | $80.22 | $138.20 | +191% | Bullish | |
| $54.45 | $89.60 | $157.66 | +225% | Bullish | |
| $58.62 | $98.93 | $177.50 | +259% | Bullish | |
| $79.10 | $150.18 | $292.04 | +445% | Bullish | |
| $179.24 | $398.31 | $868.72 | +13.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $8.91 | $27.57 | $32.27 | +0.00% |
| August 2026 | $24.64 | $29.22 | $35.67 | +5.97% |
| September 2026 | $24.67 | $29.62 | $36.87 | +1.38% |
| October 2026 | $24.36 | $29.55 | $37.35 | -0.24% |
| November 2026 | $25.67 | $31.40 | $40.18 | +6.27% |
| December 2026 | $26.95 | $33.21 | $42.98 | +5.79% |
Click any year to see its month-by-month TNGX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TNGX is projected to trade between $8.91 and $42.98, averaging $27.57 — a potential gain of 0% from today's $27.57. Price action looks broadly range-bound.
Tango Therapeutics, Inc.'s 2027 outlook centres on $32.99, within a $25.15 to $46.40 range. That is up +20% on the projected 2026 average. That marks a +20% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, TNGX could reach as high as $62.23, with a base case around $42.00 and support toward $30.63 — roughly +52% from $27.57. Momentum favours further upside here.
Expect TNGX to range from $39.61 to $86.93 through 2029. The $56.37 average target implies a +104% move from current prices. That is up +34% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The TNGX price prediction for 2030 points to an average of $66.80 (low $45.42, high $106.50) — a potential gain of +142% on today's $27.57. Momentum favours further upside here.
In 2031, TNGX is projected to trade between $50.37 and $125.34, averaging $76.38 — a potential gain of +177% from today's $27.57. That is up +14% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Tango Therapeutics, Inc.'s 2032 outlook centres on $76.18, within a $48.83 to $128.26 range. That is 0% versus the projected 2031 average. That marks a +176% change versus current levels. Momentum favours further upside here.
By 2033, TNGX could reach as high as $138.20, with a base case around $80.22 and support toward $50.04 — roughly +191% from $27.57. Buyers look set to stay in control over this stretch.
Expect TNGX to range from $54.45 to $157.66 through 2034. The $89.60 average target implies a +225% move from current prices. That is up +12% on the projected 2033 average. Momentum favours further upside here.
The TNGX price prediction for 2035 points to an average of $98.93 (low $58.62, high $177.50) — a potential gain of +259% on today's $27.57. Buyers look set to stay in control over this stretch.
In 2040, TNGX is projected to trade between $79.10 and $292.04, averaging $150.18 — a potential gain of +445% from today's $27.57. That is up +52% on the projected 2035 average. Momentum favours further upside here.
Tango Therapeutics, Inc.'s 2050 outlook centres on $398.31, within a $179.24 to $868.72 range. That is up +165% on the projected 2040 average. That marks a +13.4x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in TNGX today (≈ 36.271309 TNGX) could be worth
$14,447.21
+$13,447.21 (+1345%) by 2050 · US Dollar
Based on the average projected TNGX price of $398.31 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TNGXwould be worth at today's price.
$1,000 invested in TNGX on Jul 30, 2025 (≈ 158.730154 TNGX) would be worth
$4,376.19
+$3,376.19 (+337.6%) today · 4.38× · US Dollar
Based on a TNGX entry price of $6.3 vs. today's $27.57.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $27.45 | $1,004.37 | +0.4% |
| 1 month ago | $31.26 | $881.96 | -11.8% |
| 3 months ago | $20.98 | $1,314.11 | +31.4% |
| 6 months ago | $11.61 | $2,374.68 | +137.5% |
| 1 year ago | $6.3 | $4,376.19 | +337.6% |
| All time (5.0y) ago | $10 | $2,757 | +175.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TNGX forecast.
Our base-case forecast reaches $55.00 around 2029.
Implied market cap at $55.00: $8.95B
The multi-year forecast shows a bullish trajectory after 2026. In 2026, the min, avg, and max are $8.91, $27.64, and $45.52 respectively with a 0% ROI. By 2027, the avg climbs to $33.32 with a max of $48.43 and a 20.5% ROI, followed by 2028 with an avg of $47.14 and a max of $72.66 (70.6% ROI).
In 2029 the avg is $64.72 and the max is $104.34 (134.2% ROI). The 2030 forecast shows an avg of $75.85 and a max of $126.92 (174.4% ROI). The path continues higher through 2031 ($89.78 avg, $155.14 max, 224.8% ROI) and 2032 ($86.22 avg, $153.30 max, 211.9% ROI).
By 2033 the avg reaches $91.29 with a max of $166.51 (230.3% ROI), and 2034 shows $108.13 avg and $201.88 max (291.2% ROI). The 2035 forecast is $116.25 avg and $221.77 max (320.6% ROI). The long horizon strengthens to 2040 with an avg of $185.75 and a max of $387.18 (572% ROI), and culminates in 2050 with an avg of $524.74 and a max of $1,206.91 (1798.5% ROI).
All years carry a bullish sentiment. These figures are estimates and not guarantees.
Tap a question to reveal the answer.
In 2030 the forecast shows min $48.95, avg $75.85, max $126.92, with a 174.4% ROI and a bullish sentiment.
The forecast suggests a neutral outlook in 2026 followed by bullish momentum from 2027 onward, with rising averages and positive ROIs (e.g., 174.4% in 2030 and 1798.5% by 2050), though these are estimates and not guarantees.
Yes, the 2029 forecast lists a max of $104.34, indicating a potential to exceed $100 within that year.
The current price is $27.64 and the market cap is $4.5B.
For 2050 the forecast shows min $236.13, avg $524.74, max $1,206.91 with a 1798.5% ROI and a bullish sentiment.
Tango Therapeutics, Inc. Community Discussion
0Share your Tango Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.